Pharmacovigilance Research Group – University of Copenhagen

Pharmacovigilance Research Group

Pharmacovigilance - the science and activities relating to the detection, assessment, understanding and prevention of adverse reactions and other medicine-related problems

Our research areas are:

  • Proactive surveillance and signal detection using big healthcare data
  • Multi-database network studies of rare adverse events
  • Design of rapid risk evaluation systems

Pharmacovigilance is of major importance to the Danish society. As part of optimised treatment of patients with pharmaceutical interventions it is important to be aware of potential adverse drug reactions, how these can be detected and treated and ultimately how they potentially can be avoided.

The Pharmacovigilance Research Group is a Novo Nordisk Foundation funded initiative headed by Professor Morten Andersen. Our aim is to develop new methods and tools and generate new evidence that will shape future drug safety surveillance. Prospectively, our research will contribute to the evaluation of benefits/risks of therapy, and enable patients, healthcare professionals, regulators and the pharmaceutical industry to improve drug use and prevent drug-related problems for the benefit of public health.

We aspire to strengthen the field of pharmacovigilance as an academic discipline and create a truly interdisciplinary research field exploiting adjacent disciplines like pharmacy, regulatory science, and pharmacometrics, and benefiting from the tremendous resource of the Danish National Registers.


Collaborations

The Pharmacovigilance research Group is a member of


Examples of Master thesis projects in Pharmacovigilance Research Group

Factors influencing the choice of direct oral anticoagulants and vitamin K antagonists in non-valvular atrial fibrillation patients and evaluation of channelling

Use and safety of anti-psychotic add-on treatment to patients in anti-depressant therapy – a study based on nationwide register data

Avoiding adverse effects when dosing medications in the elderly: renal function, comorbidities and age – what is the evidence?